Skip to main content
Equibles

D. E. Shaw & Co., Inc.

Position in NVAX — Novavax Inc

CIK 1009207 New York, NY
Back to NVAX Full portfolio

Position in NVAX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$53,231,525
-$9,526,718 QoQ
Shares Held
5,650,905
-26.7% QoQ
Ownership
3.43%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#7
of 263 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 99% Shared 0% None 1%

Common Shares in NVAX Over Time

Shares Held

Position Value (USD)

Derivatives in NVAX

reported options exposure · as of Jun 30, 2026
CallValue
$2,176,020
CallShares
231,000
PutValue
$1,413,000
PutShares
150,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

D. E. Shaw & Co., Inc. holds $5,016,183,849 across 217 Biotechnology names. NVAX ranks #24 (1.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 5,877,959 $626,707,987
2 ALNY
Alnylam Pharmaceuticals, Inc.
 1,104,109 $332,369,932
3 EXEL
Exelixis, Inc.
 5,551,747 $302,070,554
4 BBIO
BridgeBio Pharma, Inc.
 3,633,007 $270,586,360
5 TGTX
Tg Therapeutics, Inc.
 3,400,808 $186,840,390
6 HALO
Halozyme Therapeutics, Inc.
 2,006,479 $157,047,110
7 AXSM
Axsome Therapeutics, Inc.
 604,753 $148,025,391
8 PTCT
Ptc Therapeutics, Inc.
 1,548,919 $126,345,322

All Filings in NVAX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,176,020 231,000
2026-06-30 $53,231,525 5,650,905
2026-06-30 $1,413,000 150,000
2026-03-31 $1,221,000 150,000
2026-03-31 $1,911,272 234,800
2026-03-31 $62,758,243 7,709,858
2025-12-31 $40,271,602 5,992,798
2025-12-31 $1,788,864 266,200
2025-12-31 $1,008,000 150,000
2025-09-30 $2,349,570 271,000
2025-09-30 $2,384,250 275,000
2025-09-30 $37,056,264 4,274,079
2025-06-30 $1,732,500 275,000
2025-06-30 $24,828,047 3,940,960
2025-06-30 $1,683,360 267,200
2025-03-31 $20,902,420 3,260,908
2025-03-31 $235,888 36,800
2024-12-31 $1,314,540 163,500
2024-12-31 $46,553,642 5,790,254
2024-09-30 $3,494,721 276,700
2024-09-30 $74,986,393 5,937,165
2024-06-30 $80,037,469 6,322,075
2024-06-30 $2,970,036 234,600
2024-03-31 $546,597 114,351
2024-03-31 $383,356 80,200
2023-12-31 $288,000 60,000
2023-12-31 $1,498,080 312,100
2023-12-31 $492,158 102,533
2023-09-30 $814,500 112,500
2023-09-30 $112,922 15,597
2023-09-30 $2,259,604 312,100
2023-06-30 $464,375 62,500
2023-06-30 $1,871,617 251,900
2023-03-31 $1,745,667 251,900
2023-03-31 $433,125 62,500
2022-12-31 $6,497,977 632,099
2022-12-31 $8,408,012 817,900
2022-12-31 $642,500 62,500
2022-09-30 $3,858,400 212,000
2022-09-30 $9,037,774 496,581
2022-09-30 $1,501,500 82,500
2022-06-30 $8,233,943 160,100
2022-06-30 $5,760,160 112,000
2022-06-30 $11,359,806 220,879
2022-03-31 $9,344,712 126,880
2022-03-31 $26,742,315 363,100
2022-03-31 $11,054,865 150,100
2021-12-31 $31,961,838 223,400
2021-12-31 $21,918,324 153,200
2021-09-30 $13,544,184 65,333

Report a Problem

Category
Description
Email (optional, for follow-up)